[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc (CLDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,028
  • Shares Outstanding, K 19,312
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,910 K
  • EBIT $ -19 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.24
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.20
  • Most Recent Earnings $-0.43 on 05/14/26
  • Next Earnings Date 08/14/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0950 +11.58%
on 07/22/26
0.1871 -43.35%
on 06/26/26
-0.0510 (-32.48%)
since 06/24/26
3-Month
0.0950 +11.58%
on 07/22/26
0.2670 -60.30%
on 04/28/26
-0.1200 (-53.10%)
since 04/24/26
52-Week
0.0950 +11.58%
on 07/22/26
10.9200 -99.03%
on 07/29/25
-9.1568 (-98.86%)
since 07/24/25

Most Recent Stories

More News
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient...

CLDI : 0.1061 (+1.05%)
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced...

CLDI : 0.1061 (+1.05%)
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)
LEGN : 22.83 (-2.97%)
RARE : 26.90 (-0.44%)
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9

ORLANDO, FL / ACCESS Newswire / June 5, 2026 / RedChip Companies will host an investor webinar with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) ("Calidi" or "the Company") on June 9, 2026, at 4:15...

CLDI : 0.1061 (+1.05%)
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)
Calidi Biotherapeutics Provides Required NYSE American Disclosure

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1061 (+1.05%)

Business Summary

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 0.1237
2nd Resistance Point 0.1171
1st Resistance Point 0.1111
Last Price 0.1061
1st Support Level 0.0985
2nd Support Level 0.0919
3rd Support Level 0.0859

See More

52-Week High 10.9200
Fibonacci 61.8% 6.7848
Fibonacci 50% 5.5075
Fibonacci 38.2% 4.2302
Last Price 0.1061
52-Week Low 0.0950

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.